Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire

03-20

SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET.

A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2520193203"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520193203\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2520193203?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-20 04:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2520193203","market":"us","top_or_hot":-1,"title":"Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/JUEQZgJG7wkAXxViajKjww--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/0c48ecf7a8b7010ea2641e33fdb6724a\" title=\"corvus_logo_large.jpg\" vspace=\"5\"/>\n<p>SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/CRVS\">Corvus Pharmaceuticals, Inc.</a> (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET.</p>\n<p>A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.</p>\n<p><strong>About Corvus Pharmaceuticals</strong><br/>Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.<br/></p>\n<p><strong>INVESTOR CONTACT:</strong><br/>Leiv Lea<br/>Chief Financial Officer<br/>Corvus Pharmaceuticals, Inc.<br/>+1-650-900-4522<br/>llea@corvuspharma.com<br/><br/><br/><br/><br/></p>\n<p><strong>MEDIA CONTACT:</strong><br/>Sheryl Seapy<br/>Real Chemistry<br/>+1-949-903-4750<br/>sseapy@realchemistry.com<br/><br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-20 04:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/corvus-pharmaceuticals-present-h-c-200100137.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership ...</p>\n\n<a href=\"https://finance.yahoo.com/news/corvus-pharmaceuticals-present-h-c-200100137.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVS","symbol_name":"Corvus Pharmaceuticals, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/corvus-pharmaceuticals-present-h-c-200100137.html","article_id":"2520193203","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520193203","pubTimestamp":1742414460,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"SOUTH SAN FRANCISCO, Calif., March 19, 2025  -- Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET.A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVS":"Corvus Pharmaceuticals, Inc.","BK4568":"美国抗疫概念","BK4139":"生物科技"},"translate_title":"乌鸦制药公司将出席H.C.温赖特第三届年度自身免疫性和炎症性疾病虚拟会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1},"content_text":"SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET.\nA webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.\nAbout Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.\nINVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+1-650-900-4522llea@corvuspharma.com\nMEDIA CONTACT:Sheryl SeapyReal Chemistry+1-949-903-4750sseapy@realchemistry.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}